Minimizing and Managing Toxicities to Maintain Patients on BTK Inhibitor Therapy

With the approval and clinical availability of BTK inhibitors, are you effectively managing the associated toxicities in your patients with lymphomas to get the most out of these agents?

Jeremy S. Abramson, MD, MMSc Released: March 8, 2019

A free resource guide for patients who are receiving BTK inhibitors, including information on FDA approvals, dosing, and potential side effects.

Use this Interactive Decision Support Tool to see strategies to assess and manage adverse events associated with BTK inhibitors from 5 renowned experts in hematologic malignancies.

Jeremy S. Abramson, MD, MMSc Farrukh T. Awan, MD Christopher R. Flowers, MD, MS John P. Leonard, MD Julie M. Vose, MD, MBA Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: September 10, 2019 Expired: No longer available for credit